CA2432370C - Vaccin attenue a flavivirus vivant caracterise par une deletion dans la proteine capsidique - Google Patents
Vaccin attenue a flavivirus vivant caracterise par une deletion dans la proteine capsidique Download PDFInfo
- Publication number
- CA2432370C CA2432370C CA2432370A CA2432370A CA2432370C CA 2432370 C CA2432370 C CA 2432370C CA 2432370 A CA2432370 A CA 2432370A CA 2432370 A CA2432370 A CA 2432370A CA 2432370 C CA2432370 C CA 2432370C
- Authority
- CA
- Canada
- Prior art keywords
- gly
- virus
- lys
- arg
- flavivirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un vaccin atténué à flavivirus vivant, renfermant un flavivirus mutant et caractérisé en ce que ce flavivirus mutant présente une délétion dans la protéine capsidique d'au moins plus de 4 acides aminés successifs, la région hydrophobe carboxy-terminale n'étant pas concernée par cette délétion.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA272/2001 | 2001-02-21 | ||
AT0027201A AT410634B (de) | 2001-02-21 | 2001-02-21 | Attenuierte lebendimpfstoffe |
PCT/AT2002/000046 WO2002066621A1 (fr) | 2001-02-21 | 2002-02-11 | Vaccins attenues a virus vivants |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2432370A1 CA2432370A1 (fr) | 2002-08-29 |
CA2432370C true CA2432370C (fr) | 2012-01-31 |
Family
ID=3670551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2432370A Expired - Fee Related CA2432370C (fr) | 2001-02-21 | 2002-02-11 | Vaccin attenue a flavivirus vivant caracterise par une deletion dans la proteine capsidique |
Country Status (10)
Country | Link |
---|---|
US (2) | US8486419B2 (fr) |
EP (1) | EP1373478B1 (fr) |
JP (2) | JP5091385B2 (fr) |
KR (1) | KR100850620B1 (fr) |
CN (3) | CN101658669A (fr) |
AT (2) | AT410634B (fr) |
AU (1) | AU2002229390B2 (fr) |
CA (1) | CA2432370C (fr) |
DE (1) | DE50206472D1 (fr) |
WO (1) | WO2002066621A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT410634B (de) * | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
AU2003258611A1 (en) * | 2002-08-13 | 2004-03-03 | Akzo Nobel N.V. | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines |
WO2004016586A2 (fr) * | 2002-08-16 | 2004-02-26 | Board Of Regents The University Of Texas System | Compositions et methodes associees aux antigenes de domaine iii de la proteine d'enveloppe du flavivirus |
CN1304579C (zh) * | 2003-07-21 | 2007-03-14 | 上海天甲生物医药有限公司 | 重组的以黄热病病毒为载体的疫苗 |
WO2005040390A1 (fr) * | 2003-07-21 | 2005-05-06 | Shanghai Tengen Biomedical Co., Ltd. | Vaccin recombine utilisant le virus de la fievre jaune comme vecteur |
CN103088038B (zh) * | 2004-07-12 | 2015-06-24 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
CA2582534A1 (fr) * | 2004-09-09 | 2006-03-16 | Research Development Foundation | Variants de flavivirus ayant une variation phenotypique et les compositions immunogeniques correspondantes |
EP1896069B1 (fr) | 2005-06-24 | 2013-03-13 | Intervet International BV | Vaccins chimères inactivés et leurs procédés d'utilisation |
WO2007098267A2 (fr) | 2006-02-27 | 2007-08-30 | The Board Of Regents Of The University Of Texas System | Flavivirus pseudo-infectieux et ses utilisations |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
HUE031617T2 (en) * | 2007-04-06 | 2017-07-28 | Takeda Vaccines Inc | Methods and preparations for live attenuated viruses |
WO2009098277A1 (fr) | 2008-02-08 | 2009-08-13 | Intercell Ag | Flavivirus mutés comprenant une délétion dans la protéine capsidique utilisés comme vaccins |
EP2589392B1 (fr) | 2008-03-05 | 2016-11-30 | Sanofi Pasteur | Procédé de stabilisation d'une composition vaccinale contenant un adjuvant |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
EP2353609A1 (fr) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Compositions et procédés d'immunisation |
WO2011101465A1 (fr) | 2010-02-19 | 2011-08-25 | Intercell Ag | Nanoparticules d'ic31 |
CN102488893B (zh) * | 2011-12-28 | 2013-07-17 | 瑞普(保定)生物药业有限公司 | 一种用细胞系生产鸭出血性卵巢炎灭活疫苗的方法及其制品 |
JP2015524421A (ja) | 2012-07-24 | 2015-08-24 | サノフィ・パスツールSanofipasteur | ワクチン組成物 |
SG11201500439RA (en) | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
WO2014083194A1 (fr) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Procédés d'induction d'anticorps |
CN103143008B (zh) * | 2013-03-07 | 2014-04-09 | 齐鲁动物保健品有限公司 | 一种鸭坦布苏病毒活疫苗及其制备方法 |
EP3355916A4 (fr) * | 2015-09-30 | 2018-08-29 | Panacea Biotec Limited | Vaccin vivant atténué recombinant et stable contre la dengue |
BE1024160B9 (fr) | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
JP7313345B2 (ja) | 2017-10-05 | 2023-07-24 | サノフィ・パスツール | デング熱に対するブースターワクチン接種のための組成物 |
CN113215117B (zh) * | 2021-05-17 | 2022-09-06 | 四川农业大学 | 一种鸭坦布苏病毒致弱活疫苗候选株及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
EP1026253B2 (fr) | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression de séquences polynucléotidiques exogènes chez un vertébré |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
ES2254055T3 (es) * | 1991-09-19 | 2006-06-16 | The United States Of America, As Represented By The Secretary, Departm. Of Health And Human Services | Flavivirus quimericos y/o de crecimiento restringido. |
FR2690921B1 (fr) * | 1992-05-06 | 1995-06-30 | Bio Merieux | Polypeptides de synthese appartenant au virus de l'hepatite c (vhc) et utilisables notamment pour detecter ce dernier. |
JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
FR2760367B1 (fr) * | 1997-03-06 | 1999-04-30 | Pasteur Merieux Serums Vacc | Composition vaccinale destinee a la prevention ou au traitement des hepatites c |
AU3844101A (en) * | 2000-02-16 | 2001-08-27 | Us Health | Avirulent, immunogenic flavivirus chimeras |
AT410634B (de) * | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
AU2003258611A1 (en) * | 2002-08-13 | 2004-03-03 | Akzo Nobel N.V. | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines |
WO2009098277A1 (fr) | 2008-02-08 | 2009-08-13 | Intercell Ag | Flavivirus mutés comprenant une délétion dans la protéine capsidique utilisés comme vaccins |
-
2001
- 2001-02-21 AT AT0027201A patent/AT410634B/de not_active IP Right Cessation
-
2002
- 2002-02-11 EP EP02710669A patent/EP1373478B1/fr not_active Expired - Lifetime
- 2002-02-11 AT AT02710669T patent/ATE323758T1/de active
- 2002-02-11 DE DE50206472T patent/DE50206472D1/de not_active Expired - Lifetime
- 2002-02-11 CN CN200910142709A patent/CN101658669A/zh active Pending
- 2002-02-11 KR KR1020037010912A patent/KR100850620B1/ko not_active IP Right Cessation
- 2002-02-11 US US10/450,649 patent/US8486419B2/en not_active Expired - Fee Related
- 2002-02-11 AU AU2002229390A patent/AU2002229390B2/en not_active Ceased
- 2002-02-11 CA CA2432370A patent/CA2432370C/fr not_active Expired - Fee Related
- 2002-02-11 JP JP2002566328A patent/JP5091385B2/ja not_active Expired - Fee Related
- 2002-02-11 WO PCT/AT2002/000046 patent/WO2002066621A1/fr active IP Right Grant
- 2002-02-11 CN CN200810149940A patent/CN101670101A/zh active Pending
- 2002-02-11 CN CNA02805217XA patent/CN1492923A/zh active Pending
-
2010
- 2010-02-05 JP JP2010024458A patent/JP2010132686A/ja not_active Ceased
-
2011
- 2011-03-15 US US13/048,412 patent/US8784839B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE323758T1 (de) | 2006-05-15 |
EP1373478B1 (fr) | 2006-04-19 |
US20040052818A1 (en) | 2004-03-18 |
US20110165230A1 (en) | 2011-07-07 |
AU2002229390B2 (en) | 2006-03-16 |
JP2004520406A (ja) | 2004-07-08 |
WO2002066621A1 (fr) | 2002-08-29 |
EP1373478A1 (fr) | 2004-01-02 |
CA2432370A1 (fr) | 2002-08-29 |
CN101670101A (zh) | 2010-03-17 |
ATA2722001A (de) | 2002-11-15 |
KR20030081457A (ko) | 2003-10-17 |
KR100850620B1 (ko) | 2008-08-05 |
DE50206472D1 (de) | 2006-05-24 |
US8784839B2 (en) | 2014-07-22 |
US8486419B2 (en) | 2013-07-16 |
JP5091385B2 (ja) | 2012-12-05 |
CN1492923A (zh) | 2004-04-28 |
CN101658669A (zh) | 2010-03-03 |
AT410634B (de) | 2003-06-25 |
JP2010132686A (ja) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2432370C (fr) | Vaccin attenue a flavivirus vivant caracterise par une deletion dans la proteine capsidique | |
JP3681369B2 (ja) | キメラおよび/または増殖制限されたフラビウイルス | |
KR100517323B1 (ko) | 키메라 플라비바이러스 백신 | |
US6696281B1 (en) | Chimeric flavivirus vaccines | |
US8029802B2 (en) | Vaccines against Japanese encephalitis virus and West Nile virus | |
US8088391B2 (en) | West nile virus vaccine | |
EP0877086B1 (fr) | Virus de la fièvre jaune (YV) recombinats vaccinaux recouvré à partir d'ADNc infectieux | |
WO1998037911A9 (fr) | Vaccins chimeres a base de flavivirus | |
WO2001039802A9 (fr) | Vaccins de flavivirus chimere |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160211 |